Fosamax and Weight gain poor - a phase IV clinical study of FDA data
Summary:
Weight gain poor is reported as a side effect among people who take Fosamax (alendronate sodium), especially for people who are female, 40-49 old, have been taking the drug for 5 - 10 years also take Premarin, and have Attention deficit hyperactivity disorder.
The phase IV clinical study analyzes which people have Weight gain poor when taking Fosamax. It is created by eHealthMe based on reports of 104,411 people who have side effects when taking Fosamax from the FDA, and is updated regularly.
What is Fosamax?
Fosamax has active ingredients of alendronate sodium. It is often used in osteoporosis. eHealthMe is studying from 105,452 Fosamax users. Check the latest studies of Fosamax.
What is Weight gain poor?
Weight gain poor is found to be associated with 298 drugs and 541 conditions by eHealthMe. Check the latest studies of Weight gain poor.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
104,411 people reported to have side effects when taking Fosamax.
Among them, 13 people (0.01%) have Weight gain poor.

Among these 13 people:
How long have people been on Fosamax when they have Weight gain poor? *
- < 1 month: 0.0 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 100 %
- 10+ years: 0.0 %
What is the gender of people who have Weight gain poor when taking Fosamax? *
- female: 76.92 %
- male: 23.08 %
What is the age of people who have Weight gain poor when taking Fosamax? *
- 0-1: 0.0 %
- 2-9: 14.29 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 42.86 %
- 50-59: 14.29 %
- 60+: 28.57 %
What are other drugs people take besides Fosamax? *
- Vyvanse: 4 people, 30.77%
- Imodium: 4 people, 30.77%
- Vitamin K: 4 people, 30.77%
- Ursodiol: 4 people, 30.77%
- Premarin: 4 people, 30.77%
- Tpn: 3 people, 23.08%
- Ranitidine: 3 people, 23.08%
- Synthroid: 2 people, 15.38%
- Dexilant: 2 people, 15.38%
- Pentasa: 2 people, 15.38%
What are other side effects people have besides Weight gain poor? *
- Urinary Tract Infection: 9 people, 69.23%
- Joint Pain: 8 people, 61.54%
- Weight Decreased: 8 people, 61.54%
- Cough: 7 people, 53.85%
- Diarrhea: 7 people, 53.85%
- Rhinorrhea (watery mucus discharge from the nose): 7 people, 53.85%
- Intestinal Obstruction: 6 people, 46.15%
- Weakness: 5 people, 38.46%
- Tongue Dry: 5 people, 38.46%
- Glucose Urine Present: 4 people, 30.77%
What are the existing conditions these people have? *
- Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 4 people, 30.77%
- Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 4 people, 30.77%
- Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 23.08%
- High Blood Pressure: 2 people, 15.38%
- Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 2 people, 15.38%
- Gleich's Syndrome (a rare disease in which the body swells up): 1 person, 7.69%
- Breast Cancer Stage I: 1 person, 7.69%
* Approximation only. Some reports may have incomplete information.
Do you take Fosamax and have Weight gain poor?
- Check whether Weight gain poor is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Fosamax:
- Fosamax (105,452 reports)
Weight gain poor treatments and more:
- Weight gain poor (3,181 reports)
How severe was Weight gain poor and when was it recovered:
Expand to all the drugs that have ingredients of alendronate sodium:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Fosamax:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Weight gain poor:
- Weight gain poor (298 drugs)
Browse all the conditions that are associated with Weight gain poor:
- Weight gain poor (541 conditions)
Related publications that referenced our studies
- Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
- Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
- Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
- Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
How the study uses the data?
The study uses data from the FDA. It is based on alendronate sodium (the active ingredients of Fosamax) and Fosamax (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Fenofibrate cause Crying? - 5 seconds ago
- Could Femara cause International Normalised Ratio Increased? - 14 seconds ago
- Fatigue in Nitrolingual Pumpspray, how severe and when it was recovered? - 20 seconds ago
- Could Chlorhexidine Gluconate cause Otitis Media? - 38 seconds ago
- Zide and Chikungunya Virus Infection for Women aged 50-59 - 41 seconds ago
- Could Baclofen cause General Physical Health Deterioration? - 46 seconds ago
- Could Linezolid cause Splenic Haemorrhage? - 48 seconds ago
- Zide and Hyperaesthesia for Women aged 50-59 - 52 seconds ago
- Could Biktarvy cause Gastroesophageal Reflux Disease? - 54 seconds ago
- Asthma and Lymphocyte Count Decreased - 56 seconds ago